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Abstract
Background: While the majority of healthcare in the US is provided in community hospitals, the epidemiology and
treatment of bloodstream infections in this setting is unknown.
Methods and Findings: We undertook this multicenter, retrospective cohort study to 1) describe the epidemiology of
bloodstream infections (BSI) in a network of community hospitals and 2) determine risk factors for inappropriate therapy for
bloodstream infections in community hospitals. 1,470 patients were identified as having a BSI in 9 community hospitals in
the southeastern US from 2003 through 2006. The majority of BSIs were community-onset, healthcare associated (n = 823,
56%); 432 (29%) patients had community-acquired BSI, and 215 (15%) had hospital-onset, healthcare-associated BSI. BSIs
due to multidrug-resistant pathogens occurred in 340 patients (23%). Overall, the three most common pathogens were S.
aureus (n = 428, 28%), E. coli (n = 359, 24%), coagulase-negative Staphylococci (n = 148, 10%), though type of infecting
organism varied by location of acquisition (e.g., community-acquired). Inappropriate empiric antimicrobial therapy was
given to 542 (38%) patients. Proportions of inappropriate therapy varied by hospital (median = 33%, range 21–71%).
Multivariate logistic regression identified the following factors independently associated with failure to receive appropriate
empiric antimicrobial therapy: hospital where the patient received care (p,0.001), assistance with $3 ADLs (p = 0.005),
Charlson score (p = 0.05), community-onset, healthcare-associated infection (p = 0.01), and hospital-onset, healthcare-
associated infection (p = 0.02). Important interaction was observed between Charlson score and location of acquisition.
Conclusions: Our large, multicenter study provides the most complete picture of BSIs in community hospitals in the US to
date. The epidemiology of BSIs in community hospitals has changed: community-onset, healthcare-associated BSI is most
common, S. aureus is the most common cause, and 1 of 3 patients with a BSI receives inappropriate empiric antimicrobial
therapy. Our data suggest that appropriateness of empiric antimicrobial therapy is an important and needed performance
metric for physicians and hospital stewardship programs in community hospitals.
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Introduction
Bloodstream infections (BSIs) are a leading cause of suffering
and death in the US. As many as 250,000 BSIs occur each year
[1], with a mortality rate of 35% and costs of up to $37,000 per
case [2,3]. In fact, BSI was one of the top causes of death in the US
in 2008, leading to more than 35,000 deaths [4].
The majority of healthcare in the US is performed in smaller,
non-teaching community hospitals._ENREF_4 The mean size of
hospitals in the US was 160 beds in 2009, and 72% of hospitals
had fewer than 200 beds [4]._ENREF_4 Of the 39 million
hospital discharges in the US in 2010, 19.9 million (51%) were
from non-teaching facilities [5]. Our understanding about the
causes and risk factors for BSI in these community hospitals,
however, is alarmingly inadequate. Prior studies on BSIs in
community hospitals have been limited to specific organisms [6,7],
single institutions, intensive care units [8] and/or patients
admitted prior to the emergence and spread of epidemiologically
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important multidrug-resistant organisms [9–14]. Even less is
known about the impact of antibacterial resistance in community
hospitals [15].
Limited available data suggest that patients with BSI are less
likely to receive appropriate therapy in community hospitals as
compared to tertiary care hospitals [15]. These treatment trends
are important, as inappropriate empiric therapy leads to a 60%
increase in mortality [16].
We undertook this study in order to 1) describe the epidemi-
ology of BSIs in a network of community hospitals and 2)




This study was reviewed and approved by the Institutional
Review Board (IRB) of Duke University Health System. Partic-
ipating community hospitals deferred to the Duke IRB (n = 5), or
reviewed and approved the study via their local IRB (n = 4).
Written patient consent was waived by all sites.
Study Design and Participating Hospitals
This retrospective cohort study included adult subjects admitted
to nine community, non-academic hospitals in North Carolina and
Virginia from January 1, 2003, through December 31, 2006
(hereafter, the ‘‘study period’’). The median bed size of partici-
pating hospitals was 151 (range 102–355) beds. All hospitals were
members of the Duke Infection Control Outreach Network
(DICON) [17]. In brief, DICON provides infection control
consulting, data feedback, education, and quality improvement
services to 42 hospitals in the southeastern US.
Patient Selection
We reviewed data from all consecutive positive blood cultures
from participating hospitals’ microbiology laboratory databases
during the study period. Patients were randomly selected from the
overall cohort. Our goal enrollment was 1,400 patients. Assuming
that 35% of patients would receive inappropriate therapy [15,18],
the study had .80% power to identify a risk factor for
inappropriate therapy that was 8% prevalent among patients
who received inappropriate therapy compared to 4% prevalent
among patients who received appropriate therapy (alpha = 0.05).
Random sampling by random number generator was performed
to ensure that subjects were included equally from all four years of
the study period.
Trained data abstractors collected all patient data by chart
review, including detailed clinical, demographic, microbiologic,
treatment data, and outcomes. A standardized data collection tool,
data dictionary, and standard operating procedure were created
prior to data abstraction. Any patient with a bloodstream infection
was considered for inclusion. Selected patients were included in
the database once. That is, if a patient’s second cases of BSI was
randomly selected for inclusion, it was excluded and a new patient
was randomly selected.
Definitions
BSIs were defined using modified Centers for Disease Control
and Prevention (CDC) criteria: $ 1 positive blood culture for all
bacterial pathogens except common skin contaminants including
Enterococci which require $ 2 positive blood cultures within
48 hours. Onset of infection was defined as the time of the first
positive blood culture. ‘‘Appropriate empiric antimicrobial ther-
apy’’ was defined as receipt of an antimicrobial agent with in vitro
activity against the infecting organism within 24 hours after the
onset of infection. Location of acquisition was defined using CDC
criteria [19] as follows: 1) ‘‘community-onset, healthcare-associat-
ed’’ was defined as a BSI occurring ,48 hours after admission
plus the presence of $1 of the following healthcare risk factors:
prior hospitalization, surgery, dialysis, or residence in a long-term
care facility in the 12 months preceding the BSI, or the presence of
an invasive device; 2) ‘‘community-acquired’’ was defined as a BSI
occurring ,48 hours after admission without one of the above
healthcare risk factors; and 3) ‘‘hospital-onset, healthcare-associ-
ated’’ was defined as a BSI that occurred $ 48 hours after hospital
admission.
Multidrug resistance was defined using consensus definitions
[20]. Charlson comorbidity index and McCabe score were used to
measure baseline severity of illness at the time of admission
[21,22]._ENREF_6 APACHE II score was calculated to measure
severity of illness at the time of infection [23]. Functional status
was measured as independent or not independent for 5 activities of
daily living (ADLs) using the Katz criteria [24]._ENREF_22 A
binary variable for functional status was created to measure severe
disability which was defined as lack of independence with $
3 ADLs. Finally, a secondary BSI was defined as a BSI that
occurred as a result of a microbiologically-diagnosed infection
from another body site, excluding central venous catheters.
Statistics
Rates were calculated as number of BSIs/1,000 patient-days.
Standard descriptive statistics were used for categorical and
continuous variables. Bivariable analyses were performed using
the Student’s t-test or Wilcoxon rank sums test, as appropriate, for
continuous variables and the x2 test for categorical variables. All
tests were two-tailed; a p-value #0.05 was considered to be
significant for all tests. Statistical analyses were performed using
SAS v9.3 (Cary, NC).
The main outcome of interest was ‘‘failure to receive
appropriate empiric antimicrobial therapy.’’ For simplicity,
patients who experienced the outcome will hereafter been labeled
as ‘‘cases.’’ Our a priori covariate of interest was location of
acquisition. Logistic regression models were created to identify
independent variables associate with the main outcome. For each
model, candidate variables were included in the full model if p,
0.2 in bivariable analysis. No correction for multiple comparisons
was made to ensure that our models were inclusive of all
appropriate candidate variables. Variables considered for inclusion
in the models were assessed for missing data. All evaluated
variables were missing fewer than 5% of the time. Thus, missing
data for these variables were imputed using unconditional
imputation: imputation of the mean for continuous variables or
the mode for categorical variables [25]. Effect measure modifica-
tion was evaluated using interaction terms with the co-variate of
interest. The Likelihood ratio test was used to determine the most
parsimonious model if group variables (e.g., Charlson score) and
specific components of the group variable (e.g., diabetes) were
candidate variables. Candidate variables were assessed for co-
linearity, and co-linear variables were removed, as necessary. The
final model was created using manual backwards selection. During
this process, removed variables were assessed for confounding. A
variable was considered to be a potential confounder if the
b-estimate for any variable changed .10% after its removal.
Finally, a class variable for ‘‘hospital’’ was included in the model,
and the generalized estimating equation method was used to
account for clustering of the outcome of interest within individual
hospitals.
BSI in Community Hospitals
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Table 1. Patient Demographics, Co-morbidities, and Hospitalization Information among 1,470 patients with bloodstream infection
(BSI) in nine community hospitals, 2003–2006a,b.
Total cohort






N = 1470 N = 542 N = 906
n (%) n (%) n (%)
Patient Demographics
Age – mean (STD) 65.3 (17.2) 65.9 (17.6) 64.9 (17.0) 0.36
Female Sex 765 (52) 285 (53) 463 (51) 0.59
Race 0.64
White 759 (52) 276 (51) 473 (52)
Black 680 (46) 251 (47) 417 (46)
Other 19 (1) 9 (1) 10 (1)
Married 611 (44) 222 (41) 380 (42) 0.71
Insurance
Medicare 1025 (70) 369 (69) 639 (71) 0.38
Medicaid 111 (8) 48 (9) 62 (7)
Private 209 (15) 78 (15) 127 (14)
None 99 (7) 32 (6) 67 (7)
BMI – mean (STD) 27.9 (8.9) 27.7 (8.5) 28.0 (9.2) 0.5
Co-morbid conditions at Admission
Need assistance with any ADL 844 (57) 334 (62) 498 (55) 0.01
Need assistance with $ 3 ADL 384 (26) 183 (34) 195 (22) ,0.0001
McCabe score at admission 0.36
1 279 (19) 114 (21) 162 (18)
2 805 (55) 295 (55) 494 (55)
3 369 (25) 126 (23) 240 (27)
On immunosuppressive medication 0.55
Corticosteroid 113 (8) 43 (8) 67 (8)
Non-corticosteroid 27 (2) 12 (2) 15 (2)
Both 7 (1) 4 (1) 3 (1)
Comorbidities
Charlson score (median, IQR) 2 (1–4) 2 (1–4) 2 (1–3) 0.02
Charlson score .3 (binary) 405 (28) 178 (33) 223 (25) 0.0007
Diabetes 626 (43) 243 (45) 373 (41) 0.17
Diabetes with end organ damage 9 (1) 6 (1) 3 (1)
Myocardial infarction 329 (22) 125 (23) 200 (22) 0.66
Congestive heart failure 313 (21) 125 (23) 184 (20) 0.22
Peripheral vascular disease 218 (15) 96 (18) 121 (13) 0.03
Cerebrovascular disease 299 (20) 106 (20) 184 (20) 0.73
Dementia 219 (15) 99 (18) 118 (13) 0.007
Chronic obstructive pulmonary disease 273 (19) 108 (20) 159 (18) 0.26
Connective tissue disease 17 (1) 8 (1) 9 (1) 0.41
Peptic ulcer disease 206 (14) 90 (17) 113 (12) 0.03
Hemiplegia 33 (2) 17 (3) 14 (2) 0.04
Liver disease 108 (7) 41 (8) 65 (7) 0.78
Chronic Kidney Insufficiency 435 (30) 161 (30) 268 (30) 0.96
End stage renal disease requiring dialysis 194 (13) 67 (12) 123 (14) 0.51
Hemodialysis 187 (12) 64 (12) 119 (13) 0.46
Peritoneal dialysis 7 (1) 3 (1) 4 (1)
History of malignancy 309 (21) 116(21) 189 (21) 0.81
BSI in Community Hospitals
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The first and primary model was created using only variables
available to treating clinicians at the onset of infection. The second
model was created in a similar fashion but candidate variables also
included variables available after the onset of infection (e.g.,
multidrug resistance and polymicrobial infection).
Results
Epidemiology of BSIs in Community Hospitals
A total of 5,124 patients had a BSI during 1,371,467 patient
days during the study period. The median rate of BSI per hospitals
was 3.5 BSIs/1000 patient days (IQR 3.0–4.2). The study cohort
consisted of a sample of 1,470 (29%) unique patients who were
randomly selected for inclusion in the study. Patients randomly
selected for inclusion had similar organism distribution to patients
not selected.
Patients were generally older (mean age 65.3 6 17.2) and
Caucasian race (n = 759, 52%) but a high proportion of patients
were African-American race (n = 680, 46%) (Table 1). A total of
1,091 (74%) patients were admitted from home, and 312 (21%)
were admitted from a nursing home; 745 (51%) patients had been
hospitalized in the prior 12 months.
The majority of BSIs were community-onset, healthcare
associated (n = 823, 56%; Table 2); 432 (29%) patients had
community-acquired BSI, and 215 (15%) had hospital-onset,
healthcare-associated BSI. BSIs due to multidrug-resistant path-
ogens occurred in 340 patients (23%). A total of 1,514 separate
pathogens were identified during the 1,470 BSIs (Table 3).
Overall, the most common pathogen was S. aureus (n = 428,
Table 1. Cont.
Total cohort






N = 1470 N = 542 N = 906
n (%) n (%) n (%)
Metastatic disease 46 (3) 19 (4) 27 (3) 0.58
HIV/AIDS 31 (2) 10 (2) 21 (2) 0.55
Transplant 11 (1) 4 (1) 7 (1) 1.0
Tobacco use ongoing 358 (24) 129 (24) 228 (25) 0.59
Alcohol use ongoing 208 (14) 67 (12) 138 (15) 0.14
Infection risks
AICD or Pacemaker present at admission 69 (5) 25 (5) 44 (5) 0.84
Documented decubitus at admission 232 (16) 91 (17) 135 (15) 0.32
Intravascular catheter present at admission 288 (20) 114 (21) 167 (19) 0.24
Urinary catheter present at admission 160 (11) 67 (12) 90 (10) 0.15
PEG present at admission 87 (6) 35 (7) 51 (6) 0.62
History of resistant organism 96 (7) 37 (7) 57 (6) 0.62
Duration of hospitalization prior to BSI (days)
median (IQR)
0 (0–0.9) 0 (0–1) 0 (0–0.7) 0.44
Hospitalization characteristics
Admitting service 0.90
Medical 1302 (89) 481 (89) 802 (89)
Surgical 101 (7) 36 (7) 63 (7)
Other 64 (4) 22 (4) 41 (5)
Admission source ,0.001
Home 1091 (74) 364 (67) 712 (79)
Nursing Home 312 (21) 140 (26) 166 (18)
Rehabilitation facility 13 (1) 8 (1) 5 (1)
Other Hospital 33 (2) 20 (4) 12 (1)
Other 19 (2) 8 (1) 11 (1)
Admitted from facility 358 (24) 168 (31) 183 (20) ,0.0001
Hospitalized in prior 12 months 745 (51) 304 (56) 430 (48) 0.002
aAbbreviations: STD = standard deviation; ADL = activity of daily living; BMI = body mass index; IQR = interquartile range; AICD = automated internal cardiac defibrillator;
PICC = peripherally inserted central catheter; PEG = percutaneous gastrostomy; MRSA = methicillin-resistant Staphylococcus aureus; ESBL = extended spectrum beta-
lactamase producing organism; VRE = vancomycin-resistant enterococci.
bMissing data: Age (n = 1), sex (n = 5), race (n = 12), marital status (n = 69), insurance (n = 22), BMI (n = 88), ambulation (n = 1), bathing (n = 1), dressing (n = 1), bowel
incontinence (n = 4), urine incontinence (n = 3), feeding (n = 1), McCabe score (n = 17), immunosuppressive medications (n = 28), tobacco use (n = 5), alcohol use (n = 8),
pacemaker present (n = 12), documented decubitus (n = 13), intravascular catheter (n = 10), urinary catheter (n = 12), percutaneous gastrostomy tube (n = 13), history of
infection or colonization due to a resistant organism (n = 40), admitting service (n = 3), admission source (n = 2), history of hospitalization in prior 12 months (n = 5).
doi:10.1371/journal.pone.0091713.t001
BSI in Community Hospitals
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28%), though type of infecting organism varied by location of
acquisition (Figure 1). The most common multidrug-resistant
pathogens were methicillin resistant Staphylococcus aureus (MRSA)
(n = 203, 13%), E. coli (n = 79, 5%), coagulase-negative staphylo-
cocci (n = 51, 3%), and Pseudomonas aeruginosa (n = 8, 0.5%).
The in-hospital mortality rate was 18% (n = 264; Table 4).
Patients with any prior healthcare exposure were almost 3-fold
more likely to die than patients without prior healthcare exposure
(OR = 2.78 95% CI 1.94–4.00). The in-hospital mortality rate was
21% (n = 170) for patients with community-onset, healthcare-
associated infection and 26% (n = 55) for hospital-onset, health-
care-associated infection.
Predictors of Failure to Receive Appropriate Empiric
Antimicrobial Therapy
Bivariable analysis. Inappropriate empiric antimicrobial
therapy was given to 542 (38%) patients (hereafter, ‘‘cases’’).
The proportion of patients who recieved inappropriate therapy
varied by hospital (median = 33%, range 21–71%). In bivariable
analysis, cases were more likely than non-cases to require
assistance with any ADL (62% v. 55%, p = 0.01), $3 ADLs
(34% v. 22%, p,0.001), and had a higher median Charlson score
(p = 0.02) (Table 1).
Cases were more likely to have prior healthcare exposure than
non-cases (p = 0.0002). More specifically, cases were more
frequently admitted from a nursing facility (p,0.001) or hospital-
ized in the prior 12 months (p = 0.002). Location of acquisition
differed between the two groups (p,0.001); cases had more
hospital-onset, healthcare-associated and less community-acquired
BSI than non-cases. Cases were more likely to have an infection
with a multidrug-resistant Gram positive organism (p,0.001).
Unadjusted in-hospital mortality was higher among cases
compared to non-cases, but the difference was not statistically
significant (p = 0.18; Table 4). Cases had longer total duration of
hospitalization (p = 0.04) and were more likely to require PICC
placement for outpatient IV antimicrobial therapy (p = 0.02). In
addition, cases had different discharge destinations than non-cases
(p = 0.01). The reasons for this difference may have been related to
previously noted differences in admission sources (ie, more cases
were admitted from facilities). In order to investigate this further,
we performed a sub-analysis limited only to patients admitted from
home (n = 1,091). In this group, a smaller proportion of cases were
discharged back to home compared with non-cases (52% v. 62%,
p = 0.003).
Multivariate Analysis. Multivariate logistic regression iden-
tified several factors independently associated with failure to
receive appropriate empiric antimicrobial therapy, including
hospital where the patient received care (p,0.001), assistance
Table 2. Infection and Treatment Data for 1,470 patients with bloodstream infection (BSI) in nine community hospitals, 2003–
2006a.
Total cohort






N = 1470 N = 542 N = 906
n (%) n (%) n (%)
Documented infection in past year 273 (20) 106 (20) 167 (19) 0.58
BSI DATA
Type of BSI 0.57
Secondary 303 (21) 107 (20) 194 (21)
Urine 173 (12) 61 (11) 111 (12)
Wound 33 (2) 13 (2) 20 (2)
Pneumonia 59 (4) 21 (4) 36 (4)
Other 38 (3) 13 (2) 25 (3)
No secondary source identified or
due to central venous catheter
1163 (79) 434 (80) 710 (79)
Location of acquisition ,0.001
Community-associated 432 (29) 126 (23) 302 (33)
Community-onset, healthcare-associated 823 (56) 314 (58) 501 (55)
Hospital-onset, healthcare-associated 215 (15) 102 (19) 103 (11)
In intensive care unit prior to BSI 87 (6) 40 (7) 44 (5) 0.05
Central line present at BSI 289 (20) 116 (22) 163 (19) 0.08
Organism
Multidrug Resistant 340 (23) 170 (32) 170 (19) ,0.0001
Resistant Gram negative pathogen 99 (7) 37 (7) 62 (7) 0.90
Resistant Gram positive pathogen 241 (17) 133 (25) 108 (12) ,0.0001
Polymicrobial 60 (4) 18 (3) 42 (5) 0.22
APACHE score at time of BSI – mean (STD) 14.5 (4.9) 14.5 (5.0) 14.4 (4.8) 0.74
aMissing data: type of BSI (n = 3), location of acquisition of BSI (n = 4), central line present at BSI (n = 51).
doi:10.1371/journal.pone.0091713.t002
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with $3 ADLs (p = 0.005), and Charlson score (p = 0.05; Table 5).
In addition, community-onset, healthcare-associated infection
(p = 0.01) and hospital-onset, healthcare-associated infection
(p = 0.02) were associated with failure to receive appropriate
empiric antimicrobial therapy using community-acquired infection
as reference. Important interaction was observed between
Charlson score and location of acquisition.
We then created a three part variable for Charlson score to
better describe this interaction: few or no co-morbidities (Charlson
score #1), moderate co-morbidities (2–4), and severe co-morbidity
($5). Among patients with community-onset, healthcare-associat-
ed BSI, the most likely to fail to receive appropriate empiric
antimicrobial therapy had no or few co-morbidities (OR = 1.69,
95% CI 1.12–2.57; p = 0.006) despite having lower acuity of illness
than patients with moderate or severe co-morbidities (APACHE II
score [IQR]: 13 [10–16] vs. 15 [12–19] vs. 15 [12–18], p,
0.0001). All patients with hospital-onset, healthcare-associated
infection were at high risk of receiving inappropriate empiric
antimicrobial therapy, though patients with severe co-morbidities
were at highest risk (OR = 3.39, 95% CI 1.34–8.54; p = 0.01).
A second model was created to determine if inclusion of the
presence of drug-resistance, a variable not available to clinicians
when they prescribed empiric antimicrobial therapy, altered any of
the independent predictors identified in Model 1. Although
infection due to a multidrug-resistant organism was strongly
associated with failure to receive appropriate empiric antibiotic
therapy (OR = 2.17, 95% CI 1.48–3.18, p,0.001), the majority of
the predictors identified in Model 1 remained independently
associated with failure to receive appropriate empiric antibiotic
therapy even with adjustment for MDR (Table 5). The exception
to this trend was Charlson score, for which the p-value changed
from 0.05 to 0.07.
Table 3. Microbiology of 1,514 isolates from 1,470 patients




Gram positive organisms 823 (54)
Staphylococcus aureus 428 (28)
Methicillin susceptible 225 (15)
Methicillin resistant 203 (13)
Coagulase negative staphylococci 148 (10)
Enterococcus 52 (3)
Group B Streptococcus 43 (3)
Group A Streptococcus 19 (1)
Viridans group streptococci 10 (1)
Gram negative organisms 660 (44)










aIsolates that led to ,10 bloodstream infections are not included.
doi:10.1371/journal.pone.0091713.t003
Figure 1. Distribution of pathogens based on location of acquisition of bloodstream infection (BSI) among 1,470 patients admitted
to 9 community hospitals, 2003–2006. [FOOTNOTE] * CA = community-acquired, CO-HCA = community-onset, healthcare-associate, HO-HCA;
hospital-onset, healthcare-associated, CoNS = coagulase negative Staphylococci.
doi:10.1371/journal.pone.0091713.g001
BSI in Community Hospitals
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Discussion
The paucity of data on BSIs in community hospitals occurs
despite the fact that the majority of health care in the US is
provided in this setting. In the current study, we used a large
cohort of patients with BSI from 9 community hospitals to identify
key aspects of the epidemiology of BSIs and risk factors for
inappropriate therapy in patients in community hospitals. Key
findings from our study included the following: 1) BSIs in
community hospitals are typically community-onset, healthcare-
associated infections; 2) the location of acquisition had a major
impact on the causative organisms; 3) empiric antimicrobial
treatment for patients with BSI in community hospitals is incorrect
in approximately 1 of 3 patients; and 4) groups with the highest
risk of receiving inappropriate empiric therapy include a) patients
with hospital-onset, healthcare associated infections b) patients
with community-onset, healthcare-associated infections and few
co-morbidities, and c) patients with impaired functional status.
Healthcare exposure preceded the onset of BSI in almost 3 of
every 4 patients in our cohort. For example, the majority of
patients in our study cohort had central venous lines, had invasive
devices present at the time of BSI, were elderly, and/or required
assistance with activities of daily living. In fact, the majority of BSIs
were community-onset, healthcare associated infections (56%).
Authors of a recent multicenter study of 7 academically-affiliated
hospitals concluded that community-onset, healthcare associated
BSIs were 2-times more frequent than community-acquired BSIs
and associated with 3-fold higher mortality [26]. Similarly, authors
of a review of BSI data from 59 hospitals demonstrated that 62%
of BSIs followed some type of healthcare exposure and the
majority of BSISs (55%) were community-onset, healthcare-
associated [27]. These findings and ours suggest that prevention
efforts aimed at hospital-acquired BSI are less likely to be as
effective or impactful as efforts to promptly and correctly provide
effective empiric therapy for healthcare-exposed patients from the
community.
The microbiology of BSIs in community hospitals has changed
over the last few decades. S. aureus was the most common cause of
BSI in our study cohort. In contrast, E. coli was the most common
cause of BSI in community hospitals prior to 2000 [10,12,14].
Further analysis of our data showed that S. aureus was the most
common pathogen in patients with community-onset, healthcare-
Table 4. Outcomes data for 1,470 patients with bloodstream infection (BSI) in nine community hospitals, 2003–2006a.
Total cohort






N = 1470 N = 542 N = 906
n (%) n (%) n (%)
In week following BSI,
Admitted to intensive care unitb 346 (26) 122 (25) 224 (27) 0.45
Central venous catheter placed 310 (21) 118 (22) 187 (21) 0.62
Intubated 183 (13) 72 (13) 106 (12) 0.39
On pressors 184 (13) 63 (12) 118 (13) 0.44
Procedure performed for BSI 170 (12) 64 (12) 102 (11) 0.75
Incision and drainage 79 (5) 31 (6) 47 (5)
Prosthesis removal 10 (1) 4 (1) 6 (1)
Other surgery 75 (5) 27 (5) 45 (5)
Hospital duration - days
Total – median (IQR) 7 (4–12) 7 (4–12) 7 (4–11) 0.04
Following BSI – median (IQR) 6 (4–11) 7 (3–12) 6 (4–10) 0.24
PICC placed for outpatient IV antibiotics 110 (8) 53 (10) 57 (6) 0.02
Died in hospital 264 (18) 106 (20) 152 (17) 0.18
Discharge status 0.01
Home 665 (46) 207 (38) 450 (50)
Home Health 103 (7) 44 (8) 59 (7)
Rehabilitation center 52 (4) 20 (4) 31 (3)
Nursing Home 283 (19) 122 (23) 155 (17)
Tertiary care hospital 77 (5) 31 (6) 45 (5)
Left hospital against medical advice 6 (1) 3 (1) 3 (1)
Other 15 (1) 7 (1) 8 (1)
Readmitted within 90 days 390 (27) 154 (29) 231 (26) 0.24
Returned to Emergency Room within 90 days 347 (25) 135 (26) 209 (25) 0.53
aMissing data: Week following BSI outcomes (n = 9), procedures after BSI (n = 24), PICC placement (n = 22), discharge status (n = 5), readmitted within 90 days (n = 9),
returned to ED (n = 85).
bExcludes 87 patients in ICU prior to BSI.
doi:10.1371/journal.pone.0091713.t004
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associated BSI and hospital-onset, healthcare-associated BSI, but
E. coli remained the most common pathogen among patients with
community-acquired BSIs. Thus, the observed emergence of S.
aureus may be related to the increasing frequency of complex
outpatient medical care and the presence of indwelling devices
prior to BSI.
In addition, patients in our study cohort more frequently had
infections due to multi-drug resistant (MDR) pathogens than in
previous studies. For example, three prior studies showed that the
frequency of MRSA as a cause of BSI in community pathogens
was 5-10 times lower (13% vs 1–3%) [9,11,12]. Overall, 23% of
patients had BSIs due to MDR pathogens in our cohort. Similar
changes in organisms and antimicrobial resistance have been
observed in tertiary care centers previously [28–30], suggesting
that BSIs in community hospitals are increasingly similar to BSIs
seen in tertiary care centers.
Approximately 1 of every 3 patients with BSI in our study failed
to receive appropriate empiric antimicrobial therapy. This
proportion of inappropriate therapy is higher than in previously
published studies from community hospitals. Approximately 20%
of patients with BSI failed to receive appropriate empiric
antimicrobial therapy prior to 2000 [11,12]. In contrast, results
from this study are similar to our recently published cohort of
patients in community hospitals with MRSA bacteremia [15] and
data published from tertiary care centers [18,31–33]. Thus, this
finding may be due to the higher prevalence of multidrug-resistant
pathogens in participating community hospitals and/or suggestive
of increasingly complex patients presenting to community
hospitals.
Recent healthcare exposure, the need for assistance with ADLs,
and infection due to a multidrug-resistant pathogen were independent
predictors for failure to receive appropriate empiric therapy in this
Table 5. Logistic Regression Modela to Identify Variables Independently Associated with Failure to Receive Appropriate Empiric
Antimicrobial Therapy.





Charlson score 0–1 (low co-morbidity) 1.69 (1.12–2.57) 0.01
Charlson score 2–4 (moderate co-morbidity) 1.49 (1.06–2.08) 0.02
Charlson score $5 (severe co-morbidity) 1.30 (0.79–2.15) 0.30
Hospital-onset, healthcare-associated *b
Charlson score 0–1 (low co-morbidity) 2.18 (1.17–4.06) 0.02
Charlson score 2–4 (moderate co-morbidity) 2.72 (1.66–4.46) ,0.001
Charlson score $5 (severe co-morbidity) 3.39 (1.34–8.54) 0.01
Require assistance with $3 ADLs 1.41 (1.12–1.79) 0.005






Charlson score 0–1 (low co-morbidity) 1.60 (1.05–2.45) 0.03
Charlson score 2–4 (moderate co-morbidity) 1.37 (0.97–1.93) 0.07
Charlson score $5 (severe co-morbidity) 1.17 (0.74–1.85) 0.5
Hospital-onset, healthcare-associated *b
Charlson score 0–1 (low co-morbidity) 1.98 (1.06–3.71) 0.03
Charlson score 2–4 (moderate co-morbidity) 2.59 (1.53–4.38) 0.0004
Charlson score $5 (severe co-morbidity) 3.39 (1.17–9.82) 0.02
Require assistance with $3 ADLs 1.32 (1.04–1.69) 0.02
Charlson score *b 0.07
Hospital *c ,0.001
Infection due to a multidrug-resistant organism 2.17 (1.48–3.18) ,0.0001
aModel included a generalized effect estimate to account for clustering among hospitals and included the following confounders: admission from a facility (p = 0.17),
presence of a central line at the time of BSI (p = 0.53), in the ICU prior to BSI onset (p = 0.59), and presence of a Foley catheter at the time of admission (p = 0.82).
bTwo interaction terms were included in the model: Interaction between Charlson score and community-onset, healthcare associated location of acquisition (0.04) and
interaction between Charlson score and hospital-onset, healthcare associated location of acquisition. No specific effect measure available for these variables due to
interaction.
cMulti-level variable, therefore no effect measure available.
doi:10.1371/journal.pone.0091713.t005
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study. One counterintuitive predictor in our study cohort, however,
deserves special emphasis: patients with few co-morbidities and
community-onset, healthcare-associated BSI were at an increased
risk of receiving inappropriate empiric antimicrobial therapy. We
observed that this group had lower APACHE II scores and was less
acutely ill at the time of onset of their bloodstream infection.
Reasons for this finding are uncertain, although we theorize that
treating clinicians were less suspicious of a severe illness such as BSI.
Thus, they may have been less aggressive in administering any
therapy or broad-spectrum antimicrobial therapy.
Our study has several important limitations. First, our
retrospective design may have led to selection and/or misclassi-
fication bias. We addressed these issues by randomly selecting
patients from the overall cohort and by training data abstractors in
the use of a standard case review form with variable definitions.
Second, our study involves patients admitted from 2003 to 2006.
Our study, however, represents the largest, most detailed study on
BSIs in community hospitals to date and provides a much needed
update. In addition, we believe the issue of inappropriate empiric
antimicrobial therapy has likely worsened over the last few years,
as resistance rates and the number of overall BSIs have increased
[34]; thus, our study may actually underestimate the problem of
inappropriate empiric antimicrobial therapy. Third, our random-
ization approach may have led to selection bias. Our cases,
however, had similar organism distribution as patients not selected
by randomization. Fourth, we did not correct for multiple
statistical comparisons. Thus, some of our ‘‘significant’’ statistical
tests may be due to Type I error. The intent of this analysis,
however, was to be exploratory and inclusive. Our findings will
require confirmation in further studies. Finally, our multicenter
study may not be generalizable to tertiary care centers.
In summary, our large, multicenter study provides the most
complete picture of BSIs in community hospitals in the US to date.
The types of BSIs seen in community hospitals have changed.
Community-onset, healthcare-associated BSI is most common,
and S. aureus is the most common cause. This shift has led to
important ramifications. One of every 3 patients with a BSI
receives inappropriate empiric antimicrobial therapy. Thus, our
data confirm that appropriateness of empiric antimicrobial
therapy is an important and needed performance metric for
physicians and hospital stewardship programs [35]._ENREF_24
Risk of inadequate therapy is highest among patients with
healthcare exposure and the disabled. Clinicians in community
hospitals must identify these important risk factors when choosing
antibiotic therapy, particularly given the adverse outcomes
associated with inadequate therapy. We believe that most risk
factors could be easily discernible using electronic data; efforts
must be made to ensure that others, such as ADLs, are routinely
included in electronic data. Ultimately, we believe an intervention
whereby physicians are automatically notified of these risk factors
when choosing empiric antimicrobial therapy is needed, particu-
larly among community hospitals in the US.
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